Back to All

Match rare disease patients to targeted therapies using DXRX Signal

18 May, 2022

Featured

When we think of rare diseases, we associate them with a small percentage of affected people. While the number of patients within individual rare disease patient populations is generally small, when we look at the high number of patients currently diagnosed with a rare disease, this equates to nearly 1 in 10 Americans (30 million people)1 

Many rare diseases worsen over time and are life limiting, making a profound impact on the lives of patients and their families and friends. The patients that live with an unknown disease endure continued suffering and are often faced with costs associated with care and lost earnings whilst they search for a diagnosis. Despite their best efforts, it takes on average 4-5 years2 for practitioners or specialists to diagnose patients with a rare disease. Furthermore, a diagnosis does not always result in treatment as only 5% of rare diseases currently have an approved treatment option3. These patients rely on the work of pharma companies to dedicate investment towards delivering breakthrough diagnosis and treatment to this underserved patient group.  

Many pharma companies actively seek to develop Precision Medicine therapies for rare diseases and one of the main challenges they face is finding patients, initially to take part in clinical trials and again when the treatment is approved for use. Traditionally, there are several ways pharma companies have executed patient finding strategies, such as working with centers of excellence, and implementing awareness and educational campaigns. These strategies require time and investment and can lead to a delay in appropriate patients receiving treatment.  

To overcome this barrier, Diaceutics developed DXRX Signal to help pharma clients identify physicians with potentially eligible patients to enroll on a clinical trial or receive treatment.  DXRX Signal delivers a weekly alert of a testing behavior to notify pharma when a specific physician (NPI) has a patient that has tested positive for their required biomarker, indicating they may be eligible for treatment. This enables pharma to engage the treating physician during the decision-making window and match those patients to targeted therapies. 

How does it work?  

Using data from 493 labs in the US that cover a wide range of conditions (including oncology, rare diseases, autoimmune, cardiovascular, and infectious diseases) and our patented Diagnostic Deductive Pathways (DDPs®) to analyze the dataDXRX Signal drills down into the specific molecular genotype of patients to identify positive test results from a particular patient cohort.  

DXRX Signal has been instrumental in identifying ‘needle in a haystack’ potentially eligible patients, this is illustrated in our latest client case study where DXRX Signal was used to locate patients with tumors of any origin with a rare oncogenic fusion for a clinical trial study. This project started with a DXRX Lab Mapping deliverable and followed on from this with DXRX Signal. DXRX Signal alerts were able to identify potentially eligible patients for inclusion in the clinical trial, allowing the clients team to engage physicians in a timely manner and enroll those eligible patients onto the trial and receive the treatment they deserve.  

Want to learn more about DXRX Signal? Request a demo today 


National Center for Advancing Translational Sciences https://rarediseases.info.nih.gov/about

Marwaha, S., Knowles, J.W. & Ashley, E.A. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome Med 14, 23 (2022). https://doi.org/10.1186/s13073-022-01026-w

3 https://www.phrma.org/en/Media/Progress-in-Fighting-Rare-Diseases

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane
London
EC4V 5EQ.

Tel: +44 (0)20 3405 0205 or [email protected]


 
Caroline Forde
Robyn Fisher
 
Kieran Breheny